MX2019000799A - Moleculas de union a gitr multimericas y usos de las mismas. - Google Patents

Moleculas de union a gitr multimericas y usos de las mismas.

Info

Publication number
MX2019000799A
MX2019000799A MX2019000799A MX2019000799A MX2019000799A MX 2019000799 A MX2019000799 A MX 2019000799A MX 2019000799 A MX2019000799 A MX 2019000799A MX 2019000799 A MX2019000799 A MX 2019000799A MX 2019000799 A MX2019000799 A MX 2019000799A
Authority
MX
Mexico
Prior art keywords
binding molecules
multimeric
gitr binding
gitr
pentameric
Prior art date
Application number
MX2019000799A
Other languages
English (en)
Spanish (es)
Inventor
BALIGA Ramesh
Tien- Yi WANG Beatrice
Alan Keyt Bruce
Original Assignee
Igm Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igm Biosciences Inc filed Critical Igm Biosciences Inc
Publication of MX2019000799A publication Critical patent/MX2019000799A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2019000799A 2016-07-20 2017-07-20 Moleculas de union a gitr multimericas y usos de las mismas. MX2019000799A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662364762P 2016-07-20 2016-07-20
PCT/US2017/043166 WO2018017889A1 (en) 2016-07-20 2017-07-20 Multimeric gitr binding molecules and uses thereof

Publications (1)

Publication Number Publication Date
MX2019000799A true MX2019000799A (es) 2019-06-03

Family

ID=60992910

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019000799A MX2019000799A (es) 2016-07-20 2017-07-20 Moleculas de union a gitr multimericas y usos de las mismas.

Country Status (9)

Country Link
US (2) US20190330360A1 (OSRAM)
EP (1) EP3487299A4 (OSRAM)
JP (1) JP2019528683A (OSRAM)
CN (1) CN109561681A (OSRAM)
AU (1) AU2017300647A1 (OSRAM)
CA (1) CA3030659A1 (OSRAM)
IL (1) IL263800A (OSRAM)
MX (1) MX2019000799A (OSRAM)
WO (1) WO2018017889A1 (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014332458B2 (en) 2013-09-05 2020-03-12 Igm Biosciences, Inc. Constant chain modified bispecific, penta- and hexavalent Ig-M antibodies
BR112016018313A8 (pt) 2014-02-10 2018-06-12 Igm Biosciences Inc Moléculas de ligação multiespecíficas iga
CN112759650B (zh) 2014-04-03 2024-10-01 Igm生物科学股份有限公司 修饰的j链
KR102435324B1 (ko) 2015-01-20 2022-08-23 아이쥐엠 바이오사이언스 인코포레이티드 종양 괴사 인자(ｔｎｆ) 수퍼패밀리 수용체 결합 분자 및 그의 용도
SI3265575T1 (sl) 2015-03-04 2021-08-31 Igm Biosciences, Inc. Vezne molekule CD20 in njihove uporabe
WO2016154593A1 (en) 2015-03-25 2016-09-29 Igm Biosciences, Inc. Multi-valent hepatitis b virus antigen binding molecules and uses thereof
AU2016249404B2 (en) 2015-04-17 2021-01-21 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
ES2996834T3 (en) 2015-09-30 2025-02-13 Igm Biosciences Inc Binding molecules with modified j-chain
EP3356401B1 (en) 2015-09-30 2020-06-24 IGM Biosciences, Inc. Binding molecules with modified j-chain
CA3021669A1 (en) 2016-05-09 2017-11-16 Igm Biosciences, Inc. Anti-pd-l1 antibodies
WO2018187702A2 (en) 2017-04-07 2018-10-11 Igm Biosciences A/S Modified human igm constant regions for modulation of complement-dependent cytolysis effector function
BR112020017296A2 (pt) 2018-03-01 2020-12-29 Igm Biosciences, Inc. Mutações de igm fc e de cadeia j que afetam a meia-vida sérica de igm
JP2022505663A (ja) * 2018-10-23 2022-01-14 アイジーエム バイオサイエンシズ インコーポレイテッド ＩｇＭ－Ｆｃベース及びＩｇＡ－Ｆｃベースの多価結合分子
CN114269785A (zh) 2019-08-15 2022-04-01 Igm生物科学股份有限公司 免疫刺激性多聚体结合分子
CN115485299A (zh) * 2020-04-22 2022-12-16 Igm生物科学股份有限公司 Pd-1激动剂多聚结合分子
US20240002526A1 (en) * 2020-11-17 2024-01-04 Igm Biosciences, Inc. Uses of effector cell engaging molecules with moieties of differing potencies
CN113151186B (zh) * 2021-02-04 2022-02-18 上海交通大学 抗人cd271的单克隆抗体及用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6290090A (en) * 1989-08-29 1991-04-08 University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
US8658159B2 (en) * 2008-06-30 2014-02-25 Versitech Limited Method to induce and expand therapeutic alloantigen-specific human regulatory T cells in large-scale
NZ590667A (en) * 2008-07-02 2013-01-25 Emergent Product Dev Seattle Tgf-b antagonist multi-target binding proteins
EP2760891B1 (en) * 2011-09-26 2018-11-07 JN Biosciences LLC Hybrid constant regions
US9382319B2 (en) * 2011-09-26 2016-07-05 Jn Biosciences Llc Hybrid constant regions
US20150038682A1 (en) * 2013-08-02 2015-02-05 Jn Biosciences Llc Antibodies or fusion proteins multimerized via homomultimerizing peptide
TW201605896A (zh) * 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
PL3148579T3 (pl) * 2014-05-28 2021-07-19 Agenus Inc. Przeciwciała anty-gitr i sposoby ich zastosowania
PL3151921T3 (pl) * 2014-06-06 2020-02-28 Bristol-Myers Squibb Company Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania
KR102435324B1 (ko) * 2015-01-20 2022-08-23 아이쥐엠 바이오사이언스 인코포레이티드 종양 괴사 인자(ｔｎｆ) 수퍼패밀리 수용체 결합 분자 및 그의 용도
EP3356401B1 (en) * 2015-09-30 2020-06-24 IGM Biosciences, Inc. Binding molecules with modified j-chain

Also Published As

Publication number Publication date
EP3487299A1 (en) 2019-05-29
EP3487299A4 (en) 2020-03-11
CN109561681A (zh) 2019-04-02
AU2017300647A1 (en) 2019-02-07
JP2019528683A (ja) 2019-10-17
CA3030659A1 (en) 2018-01-25
US20190330360A1 (en) 2019-10-31
WO2018017889A1 (en) 2018-01-25
US20220177595A1 (en) 2022-06-09
IL263800A (en) 2019-02-28

Similar Documents

Publication Publication Date Title
MX2019000799A (es) Moleculas de union a gitr multimericas y usos de las mismas.
MX2019000796A (es) Moleculas multimericas de union a ox40 y usos de las mismas.
PH12020550781A1 (en) Anti-jagged1 antibodies and methods of use
IL266100B (en) Multimeric il-15 based molecules
MX2017006094A (es) Anticuerpos anti-interleucina-33 y sus usos.
MX2017003478A (es) Anticuerpos anti-fgfr2/3 y metodos para su uso.
MY193661A (en) Anti-tim3 antibodies and methods of use
NZ762365A (en) Cd20 binding molecules and uses thereof
EP3041948A4 (en) Alternative nucleic acid molecules containing reduced uracil content and uses thereof
MX387665B (es) Péptidos, complejos, moléculas de carga y nanopartículas que contienen los mismos.
MX2020014121A (es) Agonistas parciales del receptor de insulina.
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
EP3350729A4 (en) Systems and methods for recommending personalized content
MX2015012326A (es) Anticuerpos anti-crth2 y su uso.
MX2015012334A (es) Metodos y composiciones para el control de malezas.
MX2017000895A (es) Presentacion asistida de ventanas de aplicaciones.
MX2017001458A (es) Dimensionamiento y posicionamiento basados en region de ventanas de aplicacion.
TW201613966A (en) SynTac polypeptides and uses thereof
MX2016007541A (es) Moléculas modificadas de ácido nucleico y usos de las mismas.
MX2016015162A (es) Anticuerpos anti - gpc3 e inmunoconjugados.
MX2018004674A (es) Moduladores de interacción de sestrina-gator2 y sus usos.
MX2016004853A (es) Metodos de uso de anticuerpos anti-ly6e.
IL267589A (en) adam9 binding molecules and methods for their use
MX2024000004A (es) Proteinas de fusion de inhibidor de tripsina urinaria (uti).
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.